Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6234-6243

  Lucasti, Christopher ^a   Vasile, Liviu ^b   Sandesc, Dorel ^c   Venskutonis, Donatas ^d   McLeroth, Patrick ^e   Lala, Mallika ^f   Rizk, Matthew L ^f   Brown, Michelle L ^f   Losada, Maria C ^f   Pedley, Alison ^f   Kartsonis, Nicholas A ^f   Paschke, Amanda ^f  

^a South Jersey Infectious Disease   (United States)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^e 206 Carnegie Center   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; PLACEBO; RELEBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; CILASTATIN; CILASTATIN, IMIPENEM DRUG COMBINATION; DRUG COMBINATION; IMIPENEM; MK-7655;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; BACTEROIDES INFECTION; CHOLECYSTITIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM PERFORATION; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LIVER ABSCESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PERITONITIS; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS INFECTION; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SPLEEN ABSCESS; STREPTOCOCCUS INFECTION; TREATMENT RESPONSE; VOMITING; ADOLESCENT; BACTERIAL INFECTIONS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL INFECTIONS; CILASTATIN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84992360092     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00633-16     Document Type: Article

References (32)

1. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081. http://dx.doi.org/10.1086/533452.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
3. Curiao T, Morosini MI, Ruiz-Garbajosa P, Robustillo A, Baquero F, Coque TM, Canton R. 2010. Emergence of blaKPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J Antimicrob Chemother 65:1608-1614. http://dx.doi.org/10.1093/jac/dkq174.
4. Giani T, D'Andrea MM, Pecile P, Borgianni L, Nicoletti P, Tonelli F, Bartoloni A, Rossolini GM. 2009. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 carbapenemase. J Clin Microbiol 47:3793-3794. http://dx.doi.org/10.1128/JCM.01773-09.
5. Gregory CJ, Llata E, Stine N, Gould C, Santiago LM, Vazquez GJ, Robledo IE, Srinivasas A, Tomashek KM. 2010. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 31:476-484. http://dx.doi.org/10.1086/651670.
6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597-602. http://dx.doi.org/10.1016/S1473-3099(10)70143-2.
7. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228-236. http://dx.doi.org/10.1016/S1473-3099(09)70054-4.
8. Österblad M, Kirveskari J, Koskela S, Tissari P, Vuorenoja K, Hakanen AJ, Vaara M, Jalava J. 2009. First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009. Euro Surveill 14:19349.
9. Roche C, Cotter M, O'Connell N, Crowley B. 2009. First identification of class A carbapenemase-producing Klebsiella pneumoniae in the Republic of Ireland. Euro Surveill 14:19163.
10. Tóth Á, Damjanova I, Puskás E, Jánvári L, Farkas M, Dobák A, Borocz K, Paszti J. 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 29:765-769. http://dx.doi.org/10.1007/s10096-010-0921-3.
11. Wendt C, Schütt S, Dalpke AH, Konrad M, Mieth M, Trierweiler-Hauke B, Weigand MA, Zimmermann S, Biegler K, Jonas D. 2010. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis 29:563-570. http://dx.doi.org/10.1007/s10096-010-0896-0.
12. Chopra I, Schofield C, Everett M, O'Neill A, Miller K, Wilcox M, Frere JM, Dawson M, Czaplewski L, Urleb U, Courvalin P. 2008. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 8:133-139. http://dx.doi.org/10.1016/S1473-3099(08)70018-5.
13. Lefevre S, Debat H, Thomas D, Friboulet A, Avalle B. 2001. A suicide-substrate mechanism for hydrolysis of β-lactams by an anti-idiotypic catalytic antibody. FEBS Lett 489:25-28. http://dx.doi.org/10.1016/S0014-5793(01)02075-0.
14. Overturf GD. 2010. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J 29:68-70. http://dx.doi.org/10.1097/INF.0b013e3181c9c118.
15. Thomson JM, Bonomo RA. 2005. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: B-lactams in peril! Curr Opin Microbiol 8:518-524.
16. Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorso KL, Park Y-W, Ogawa AM, Wisniewski D, Hermes J, Blizzard TA, Hammond ML, Motyl MR. 2010. In vitro activity of the class A and C β-lactamase inhibitor MK-7655, abstr F1-2139. Abstr 50th Intersci Conf Antimicrob Agents Chemother.
17. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286-2290. http://dx.doi.org/10.1093/jac/dkt178.
18. Young K, Motyl M. 2015. Retrospective analysis of the effect of MK-7655 (relebactam) on imipenem non-susceptible Pseudomonas aeruginosa and KPC-expressing Enterobacteriaceae, abstr C-156. Abstr 55th Intersci Conf Antimicrob Agents Chemother.
19. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753-3757. http://dx.doi.org/10.1128/AAC.05927-11.
20. Powles MA, Galgoci A, Misura A, Liberator P, Hammond M. 2010. In vivo efficacy of the beta-lactamase inhibitor, MK-7655, in combination with imipenem in murine models of infection, abstr F1-2140. Abstr 50th Intersci Conf Antimicrob Agents Chemother.
21. Wu J, Racine F, Rizk ML, Wismer MK, Harradine P, Young K, Motyl M. 2014. Exploring PK/PD relationship of a novel beta-lactamase inhibitor MK-7655 in combination with imipenem in a hollow fiber infection model, abstr P1740. Abstr 24th Annu Eur Congress Clin Microbiol Infect Dis.
22. Tang W, Dingley K, Blizzard L, Young K, Motyl M. 2010. MK-7655 human dose projection based on its pharmacokinetics in preclinical species, abstr F1-2141. Abstr 50th Intersci Conf Antimicrob Agents Chemother.
23. Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW. 2015. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother 59:790-795. http://dx.doi.org/10.1128/AAC.03706-14.
24. Rizk ML, Ahmed GF, Young K, Motyl M, Butterton J, Racine F, Wu J, Li C, Wenning L. 2012. A semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for MK-7655, a novel beta-lactamase inhibitor (BLI) for use in combination with imipenem/cilastatin, abstr A-1763. Abstr 52nd Intersci Conf Antimicrob Agents Chemother.
25. Young K, Hackel M, Lascols C, Bouchillon S, Badal R. 2012. Response to imipenem plus MK-7655, a novel β-lactamase inhibitor, in a surveillance study population of P. aeruginosa from SMART 2009, abstr C2-724. Abstr 52nd Intersci Conf Antimicrob Agents Chemother.
26. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. 1996. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 15:913-921. http://dx.doi.org/10.1007/BF01690508.
27. Lee YR, McMahan D, McCall C, Perry GK. 2015. Complicated intra-abdominal infections: the old antimicrobials and the new players. Drugs 75:2097-2117. http://dx.doi.org/10.1007/s40265-015-0506-7.
28. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50:133-164. http://dx.doi.org/10.1086/649554.
29. Miettinen O, Nurminen M. 1985. Comparative analysis of two rates. Stat Med 4:213-226. http://dx.doi.org/10.1002/sim.4780040211.
30. Center for Drug Evaluation and Research. 2015. Guidance for industry: complicated intra-abdominal infections: developing drugs for treatment. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm321390.pdf.
31. Neuwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. 1995. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 36: 335-342. http://dx.doi.org/10.1093/jac/36.2.335.
32. Villar HE, Danel F, Livermore DM. 1997. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. J Antimicrob Chemother 40:365-370. http://dx.doi.org/10.1093/jac/40.3.365.